Human Molecular Genetics, 2000, Vol. 9, No. 15 2297-2304
© 2000 Oxford University Press
RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia
Department of Biology and Genetics, University of Milan, Medical Faculty, 20133 Milan, Italy and 1Division of Hematology, Niguarda Hospital, 20162 Milan, Italy.
The SH2 domain-containing tyrosine phosphatase PTPN6 (SHP-1, PTP1C, HCP) is a 68 kDa cytoplasmic protein primarily expressed in hematopoietic cell development, proliferation and receptor-mediated mitogenic signaling pathways. By means of direct dephosphorylation, it down-regulates a broad spectrum of growth-promoting receptors, including the Kit tyrosine kinase, activated to elicit a prominent cascade of intracellular events by stem cell factor binding. The pivotal contribution of PTPN6 in modulating myeloid cell signaling has been revealed by the finding that shp-1 mutation is responsible for the overexpansion and inappropriate activation of myelomonocytic populations in motheaten (me/me) and motheaten viable (mev/mev) mice. Association of PTPN6 with c-Kit and negative modulation of the myeloid leukocyte signal transduction pathways prompted us to examine the expression of the protein tyrosine phosphatase PTPN6 gene in CD34+/CD117+ blasts from acute myeloid leukemia patients. We identified and cloned cDNAs representing novel PTPN6 mRNA species, derived from aberrant splicing within the N-SH2 domain leading to retention of intron 3. Sequence analysis of cDNA clones revealed multiple A
G editing conversions. The editing of PTPN6 mRNA mainly occurred as an AG conversion of A7866, which represents the putative branch site in IVS3 of PTPN6 mRNA. Evidence that editing of A7866 abrogates splicing has been obtained in vitro by using an edited clone and its backward clone generated by site-directed mutagenesis. The level of the aberrant intron-retaining splice variant, evaluated by semi-quantitative RT–PCR, was lower in CD117+-AML bone marrow mononuclear cells at remission than at diagnosis, suggesting the involvement of post-transcriptional PTPN6 processing in leukemogenesis.
+ To whom correspondence should be addressed. Tel: +39 02 23693226; Fax: +39 02 70602472; Email: lidia.larizza@unimi.it
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Nakase, J. Cheng, Q. Zhu, and W. A. Marasco Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells and its silencing in HTLV-1-transformed T cells J. Leukoc. Biol., January 1, 2009; 85(1): 165 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. F. Peterson, A. Boyapati, E.-Y. Ahn, J. R. Biggs, A. J. Okumura, M.-C. Lo, M. Yan, and D.-E. Zhang Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts Blood, August 1, 2007; 110(3): 799 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ryman, N. Fong, E. Bratt, D. L. Bentley, and M. Ohman The C-terminal domain of RNA Pol II helps ensure that editing precedes splicing of the GluR-B transcript RNA, July 1, 2007; 13(7): 1071 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Wilson, J. Cheung, D. W. Martindale, S. W. Scherer, and B. F. Koop Comparative analysis of the paired immunoglobulin-like receptor (PILR) locus in six mammalian genomes: duplication, conversion, and the birth of new genes Physiol Genomics, November 21, 2006; 27(3): 201 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Tam, M. Gomez, A. Chadburn, J. W. Lee, W. C. Chan, and D. M. Knowles Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas Blood, May 15, 2006; 107(10): 4090 - 4100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-F. Honorat, A. Ragab, L. Lamant, G. Delsol, and J. Ragab-Thomas SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling Blood, May 15, 2006; 107(10): 4130 - 4138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M.P. Desterro, L. P. Keegan, E. Jaffray, R. T. Hay, M. A. O'Connell, and M. Carmo-Fonseca SUMO-1 Modification Alters ADAR1 Editing Activity Mol. Biol. Cell, November 1, 2005; 16(11): 5115 - 5126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Du, S. E. Spence, N. A. Jenkins, and N. G. Copeland Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis Blood, October 1, 2005; 106(7): 2498 - 2505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Shikama, T. Shichishima, I. Matsuoka, P. T. Jubinsky, C. A. Sieff, and Y. Maruyama Accumulation of an intron-retained mRNA for granulocyte macrophage-colony stimulating factor receptor common {beta} chain in neutrophils of myelodysplastic syndromes J. Leukoc. Biol., May 1, 2005; 77(5): 811 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Flomen, J. Knight, P. Sham, R. Kerwin, and A. Makoff Evidence that RNA editing modulates splice site selection in the 5-HT2C receptor gene Nucleic Acids Res., April 15, 2004; 32(7): 2113 - 2122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Dawson, C. L. Sansam, and R. B. Emeson Structure and Sequence Determinants Required for the RNA Editing of ADAR2 Substrates J. Biol. Chem., February 6, 2004; 279(6): 4941 - 4951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Maas, A. Rich, and K. Nishikura A-to-I RNA Editing: Recent News and Residual Mysteries J. Biol. Chem., January 10, 2003; 278(3): 1391 - 1394. [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Heinrich, C. D. Blanke, B. J. Druker, and C. L. Corless Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies J. Clin. Oncol., March 15, 2002; 20(6): 1692 - 1703. [Abstract] [Full Text] [PDF]
|
|